Gynecologic Oncology

Uterine cancer is currently the only cancer type not covered by the World Trade Center (WTC) Health Program.

Emily K. Hill, MD, reviews the current US HPV and cervical cancer screening guidelines from the American Cancer Society, American College of Obstetricians and Gynecologists, and the American Society for Colposcopy and Cervical Pathology and discusses the differences within.

Experts in obstetric and gynecologic management examine conventional cervical cancer screening strategies and consider their specificity and sensitivity targets.

Drs Mark H. Stoler, Emily K. Hill, Sangini S. Sheth, and Thomas C. Wright comment on the general awareness around HPV and cervical cancer in patients as well as the importance of increasing routine cervical cancer screening approaching those conversations with patients.

Emily K. Hill, MD; Sangini S. Sheth, MD, MPH, FACOG, and Mark. H. Stoler, MD, FASCP, review the rationale of screening for HPV and vaccinating patients to prevent progression to cervical cancer.

Family history assessment, genetic screening are key to prevention.

Pathology expert Mark H. Stoler, MD, discussed the BD Onclarity™ HPV Assay for primary HPV screening and what it means for the future of cervical cancer detection.

Cancer programs seek to remove barriers to screenings.

A study published in the Journal of Ovarian Research examines factors that may cause endometriosis to progress to ovarian cancer.

Frontline maintenance treatment with selinexor resulted in a statistically significant improvement in median progression-free survival vs placebo in patients with advanced or recurrent endometrial cancer, meeting the primary end point of the phase 3 SIENDO trial.

The campaign emphasizes the importance of annual cancer screenings with the Queen of Hip-Hop Soul

Sarah Lee, MD, MBA, discusses the use of checkpoint inhibitors in endometrial cancer, research regarding the association between MSI-H, dMMR, and TMB-H disease, and the importance of broad molecular testing to ensure all eligible patients are appropriately matched to immunotherapeutic options.

Amer Karam, MD, discusses the role of secondary cytoreductive surgery in ovarian cancer and the need for careful patient selection, plus the results from 3 clinical trials and the key differences between these efforts.

Cortney Eakin, MD, discusses alarming trends in uterine cancer histologies in Black women and some of the potential underlying risk factors at play.

Consensus group discussion resulted in a shift from results-based to risk-based management for cervical cancer screening.

Women are less likely to be diagnosed with bladder cancer, but that does not make the disease any less fatal for this population of patients.

A prospective observational screening study has concluded a cytology dual-stain (DS) biomarker effectively triages women who test positive for primary human papillomavirus (HPV) and are at higher risk of developing cervical cancer, irrespective of the HPV genotype.

Human papillomavirus (HPV) vaccination has significantly decreased the incidence and mortality of cervical cancer in girls and women between the ages of 15 and 24, according to a research letter in JAMA Pediatrics.

The vaccine, which protects patients from seven different strains related to HPV-related cancers, may be considered part of routine oncology care for survivors.

Dr. Don S. Dizon discusses how cancer centers can be more inclusive to the LGBTQ+ community, from the naming of the institutions to the types of magazines found in the waiting rooms.

Certain post-menopausal women with HR-positive, HER2-negative breast cancer may be able to only undergo endocrine therapy after surgery – sparing themselves from the chemotherapy side effects.

The study results — which were presented during the 2021 San Antonio Breast Cancer Symposium — indicated that elacestrant, a selective estrogen receptor degrader (SERD), led to a 30% reduction in the risk of disease progression or death compared with standard of care in the study population.

First-line maintenance treatment with the PARP inhibitor niraparib yielded a clinically meaningful and statistically significant improvement in progression-free survival vs placebo in Chinese patients with platinum-responsive advanced ovarian cancer, regardless of biomarker status, according to data from the phase 3 PRIME trial.

The combination of lenvatinib plus pembrolizumab induced durable responses with a manageable safety profile in adults with previously treated, advanced endometrial cancer, according to a long-term follow-up analysis of a phase 1b/2 study (NCT02501096).

Disparities across the globe continue to surface as we approach year 2 of the COVID-19 pandemic, especially in health care. As one considers its implications, a research team from the American Cancer Society investigated its potential impact on early cancer detection.